ACTIV in CHF

ACTIV in CHF

Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure. A trial assessing the short- and intermediate-term effects of tolvaptan (Samsca, OPC-41061), a vasopressin receptor 2 antagonist.
Conclusion 60-day mortality was lower in tolvaptan patients with renal dysfunction or severe systemic congestion. It was approved by the FDA in 2009 for treating hyponatremia associated with congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormone (SIADH).
References in periodicals archive ?
Randomized, controlled trials are extremely rare in hospitalized patients with worsening heart failure," said ACTIV in CHF lead investigator, Mihai Gheorghiade, MD, Associate Chief, Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL.